Conflicts of interest.
JPG: reports having received speaker fees, fees for board memberships and travel support from Gilead, MSD and Pfizer; Grant to the University Hospital of Rennes from the “Programme Hospitalier de Recherche Clinique Interrégional” 2013-2020 of the French Ministry of Health for ECENVIR study.
CG reports having received speaker fees, travel support from Pfizer, MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Pfizer, MSD, SOS Oxygène, ISIS Medical, Vivisol, Elivie, and AstraZeneca. Material and logistics support to all participating centres for NEBULAMB study from the firm PARI GmbH France. Grant to the University Hospital of Poitiers from the “Programme Hospitalier de Recherche Clinique Interrégional” 2012 of the French Ministry of Health for NEBULAMB study and 2017 for CPAAARI study.
DWD and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company, and share options in TFF Pharma. He acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Bright Angel Therapeutics, Pfizer, Omega, Novacyt and Cipla. He sits on the DSMB for a SARS CoV2 vaccine trial. In the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, BioRad, Basilea, Mylan, Biorad and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and recently joined the One World Guideline for Aspergillosis.”
Author’s contribution. JPG, CG and DWD: conceptualization and writing original draft.
Legend Figure 1. Fungal exposome impacts on lungs and strategies of prevention of allergic fungal diseases. ABPA: allergic broncho-pulmonary aspergillosis ; SAFS: severe asthma with fungal sensitization.